# 2026-05772: FDA Downgrades Skin Cancer Gadgets to Speed Up Doctor Tools

2026-05772, General and Plastic Surgery Devices; Reclassification of Optical Diagnostic Devices for Melanoma Detection and Electrical Impedance Spectrometers, To Be Renamed Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-03-25, effective 2026-04-24; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-05772
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05772
- Title: General and Plastic Surgery Devices; Reclassification of Optical Diagnostic Devices for Melanoma Detection and Electrical Impedance Spectrometers, To Be Renamed Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 14445
- Published: 2026-03-25
- Effective: 2026-04-24
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

FDA Downgrades Skin Cancer Gadgets to Speed Up Doctor Tools

## Summary

The FDA is changing the rules for certain skin cancer detection devices, moving them from a strict category (Class III) to a less strict one (Class II) with special safety checks. These devices, now called software-aided tools for skin lesion diagnosis, must be used by doctors trained in skin cancer. The new rules start April 24, 2026, making it easier and safer for doctors to use these helpful tools without extra costly hurdles.

## Abstract

The Food and Drug Administration (FDA) is issuing a final order reclassifying optical diagnostic devices for melanoma detection (product code OYD) and electrical impedance spectrometers (product code ONV), both postamendments class III device types, into class II (special controls), subject to premarket notification. FDA is also renaming and codifying these devices under the new classification regulation named "software-aided adjunctive diagnostic devices for use on skin lesions by physicians trained in the diagnosis and management of skin cancer." FDA is also establishing the special controls necessary to provide a reasonable assurance of safety and effectiveness of these devices.

## Effects PRIA read

- Manufacturers can use 510(k) instead of PMA: benefit, high. Starting April 24, 2026, certain skin‑lesion diagnostic devices are reclassified from Class III to Class II so manufacturers may seek FDA clearance through a 510(k) premarket notification instead of a full premarket approval (PMA). This reduces the regulatory burden on device makers and usually sho…
- Devices limited to trained physicians: benefit, medium. The newly named devices are intended for prescription use only and must be used by physicians trained in the diagnosis and management of skin cancer (for example, dermatologists). They are not intended for standalone use and use for general screening or triage is outside the scope of this order.
- Labeling must show test performance and limits: benefit, medium. Manufacturers must include in device labeling performance measures (including sensitivity, specificity, and confidence intervals), a description of the patient population used to develop or train the algorithm, limitations of device performance, and required user qualifications. Labeling must state…
- Broader clinical testing and subgroup analysis required: cost, high. The special controls require clinical testing that evaluates patients across risk factors representing the intended population (including age, body site, and skin phototype) and require subgroup analyses. Standalone device testing must demonstrate at least 90 percent sensitivity for lesions with hi…
- Post-market surveillance and real‑world data requirements: mixed, medium. The special controls require data from both premarket clinical validation testing and post‑market surveillance acquired under anticipated conditions of use, unless FDA determines post‑market data is not required based on the totality of premarket data.
- Adaptive algorithms likely excluded: cost, medium. FDA states devices with algorithms that change or adapt over time (non‑fixed algorithms) would likely raise different safety and effectiveness questions and therefore would not be found substantially equivalent under this classification regulation.
- Significant algorithm changes need new review: cost, medium. If a cleared device maker intentionally changes the device algorithm and the change exceeds the regulatory threshold in 21 CFR 807.81(a)(3), FDA would review the change in a premarket submission (new 510(k) or other submission as appropriate).
- Reclassification effective date: mixed, low. The FDA final order reclassifying these devices to Class II and establishing the special controls becomes effective on April 24, 2026.
- FDA expects increased patient access: benefit, medium. FDA states it expects reclassification will enable more manufacturers to develop these adjunctive diagnostic tools so patients will benefit from increased and more timely access to such devices that meet the special controls.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05772 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/25/2026-05772/general-and-plastic-surgery-devices-reclassification-of-optical-diagnostic-devices-for-melanoma)
- [2026-05772 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-25/pdf/2026-05772.pdf)

## Related
- [Previous: 2026-05767, Definition of a Ski Area](https://policyrisk.com/federal-register/2026-05767)
- [Next: 2026-05773, Dimethylpolysiloxane in Pesticide Formulations; Exemption From the Requirement…](https://policyrisk.com/federal-register/2026-05773)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05772 (as of 2026-06-11).
